C
CervoMed Inc.
CRVOCIK 0001053691NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
$4.01M
Net Income
$-26.97M
Total Assets
$22.88M
Equity
$18.22M
Shares Out
9.26M
Op. Cash Flow
$-23.45M
Business
CervoMed Inc. is a clinical-stage biotechnology company developing treatments for age-related neurologic disorders, with a lead focus on neflamapimod, an oral, brain-penetrant p38α inhibitor. Its main product candidate is neflamapimod, pursued as a disease‑modifying therapy for dementia with Lewy bodies (DLB) and being evaluated in Phase 2b and other clinical trials, with additional programs in FTD and ischemic stroke recovery. Business activities center on clinical development, regulatory interactions and potential strategic collaborations. Clinical programs and potential commercialization efforts target North America and Europe, relying on third‑party contract manufacturers and partners for production and distribution.
Summary from filing dated 2025-03-17
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Grant revenue | 4 | 10 | 7 | 0 | — | |
| Research and development | 22 | 19 | 8 | 1 | 8 | |
| General and administrative | 10 | 9 | 7 | 2 | 7 | |
| Total operating expenses | 32 | 28 | 15 | 3 | — | |
| Loss from operations | −28 | −18 | −8 | −3 | −25 | |
| Other expense | −8,327 | −991 | 5 | −2 | — | |
| Interest income | 1 | 2 | 219,430 | 62,226 | — | |
| Total other income, net | 1 | 2 | 6 | −2 | — | |
| Net loss | −27 | −16 | −2 | −6 | −24 | |
| Net loss per share of common stock, basic and diluted (in dollars per share) | −2.98 | −2.02 | −0.82 | −11.2 | −12.38 | |
| Weighted average shares outstanding, basic and diluted (in shares) | 9 | 8 | 3 | 518,140 | — | |
| Net unrealized (loss) gain on marketable securities | −50,381 | 56,197 | 0 | −35,375 | 0 | |
| Total comprehensive loss | −27 | −16 | −2 | −16 | −24 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 8 | 9 | 8 | 4 | 37 | |
| Marketable securities | 13 | 30 | 0 | 12 | 0 | |
| Prepaid expenses and other current assets | 1 | 2 | 1 | 64,127 | 510,015 | |
| Deferred offering costs | 300,000 | 0 | — | — | — | |
| Grant receivable | 426,993 | 2 | 915,404 | 0 | — | |
| Total current assets | 23 | 43 | 10 | 4 | 38 | |
| Total assets | 23 | 43 | 10 | 4 | 38 | |
| Accounts payable | 1 | 2 | 662,471 | 97,302 | 947,495 | |
| Accrued expenses and other current liabilities | 3 | 2 | — | — | — | |
| Total current liabilities | 5 | 4 | — | — | 3 | |
| Total liabilities | 5 | 4 | 3 | 13 | 3 | |
| Common stock, $0.001 par value: 1,000,000,000 shares authorized at December 31, 2025 and 2024: 9,252,719 and 8,702,719 shares issued and outstanding at December 31, 2025 and 2024, respectively | 9,252 | 8,702 | 5,674 | 518 | 2,038 | |
| Additional paid-in capital | 116 | 110 | 62 | 19 | 165 | |
| Accumulated other comprehensive income | 5,816 | 56,197 | 0 | −35,375 | 0 | |
| Accumulated deficit | −98 | −71 | −54 | −52 | −130 | |
| Total stockholders' equity | 18 | 39 | 7 | −33 | 35 | |
| Total liabilities and stockholders' equity | 23 | 43 | 10 | 4 | 38 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Accretion of discount on marketable securities, net | −854,077 | −1 | — | — | — | |
| Stock-based compensation expense | 1 | 1 | 407,632 | 333,835 | 897,260 | |
| Prepaid expenses and other current assets | 638,355 | −641,089 | −1 | 85,104 | −248,997 | |
| Deferred offering costs | −310,581 | 0 | — | — | — | |
| Accounts payable | −67,322 | 848,969 | 565,169 | 79,154 | — | |
| Accrued expenses and other liabilities | 834,157 | 690,290 | 1 | 215,679 | — | |
| Grant receivable | 2 | −1 | −915,404 | — | — | |
| Net cash used in operating activities | −23 | −17 | −7 | −3 | −15 | |
| Purchase of marketable securities | −25 | −48 | 0 | −38 | 0 | |
| Maturities of marketable securities | 44 | 19 | 0 | 26 | 0 | |
| Net cash provided by (used in) investing activities | 18 | −29 | 0 | −12 | 4,000 | |
| Proceeds from sale of common stock, prefunded warrants and common stock warrants | 0 | 46 | — | — | — | |
| Net cash provided by financing activities | 5 | 46 | 11 | 0 | 33 | |
| Net (decrease) increase in cash and cash equivalents | −764,027 | 1 | 4 | −3 | 19 | |
| Stock options granted in lieu of cash bonus | 0 | 255,724 | — | — | — | |
| Cashless exercise of pre-funded warrants | 0 | 945 | 0 | — | — | |
| Deferred offering costs in accounts payable | 10,000 | 0 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro